Valuation: Castle Biosciences, Inc.

Market Cap 743M 652M 605M 556M 1.05B 71.78B 1.06B 7.21B 2.82B 35.09B 2.79B 2.73B 121B P/E 2026 *
-17.5x
P/E 2027 * -25.9x
Enterprise Value 743M 652M 605M 556M 1.05B 71.78B 1.06B 7.21B 2.82B 35.09B 2.79B 2.73B 121B EV / Sales 2026 *
2.11x
EV / Sales 2027 * 1.89x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day+1.22%
1 week+7.31%
Current month+4.03%
1 month+17.47%
3 months+0.94%
6 months-39.46%
Current year-36.22%
1 week 23.25
Extreme 23.25
25.13
1 month 21.05
Extreme 21.05
25.13
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.58
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 01/09/2007
Director of Finance/CFO 56 01/12/2017
Chief Tech/Sci/R&D Officer - 01/07/2021
Director TitleAgeSince
Director/Board Member 64 01/09/2007
Chairman 64 01/09/2014
Director/Board Member 70 06/12/2018
Date Insider Type Main position Quantity % Market Cap.
7/14/26 A Fiscal year

Founder

5,272 0.0174%
7/1/26 A Fiscal year

Founder

22,264 0.0734%
7/1/26 A Sell

Chief Operating Officer

-8,586 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+1.22%+7.31%+48.39%+48.30% 743M
-1.01%-5.85%+230.30%+300.29% 20.19B
-0.78%-0.50%-41.01%-26.95% 9.47B
-3.09%+2.19%+46.19%+19.50% 7.03B
-0.32%+2.75%+307.71%-21.53% 5.99B
+5.53%+11.21%-10.86%-21.77% 5.32B
+2.37%+34.06%+109.23%+134.13% 4.94B
-2.23%-9.26%-45.63% - 4.45B
-0.62%-3.85%-24.72%-28.25% 4.08B
+0.15%+2.70%-14.88%-38.73% 2.76B
Average +0.12%+1.94%+60.47%+40.55% 6.5B
Weighted average by Cap. -0.33%+0.36%+101.63%+102.05%

Financials

2026 *2027 *
Net sales 352M 309M 287M 263M 496M 34.02B 504M 3.42B 1.34B 16.63B 1.32B 1.29B 57.46B 393M 344M 320M 294M 554M 37.94B 562M 3.81B 1.49B 18.55B 1.47B 1.44B 64.08B
Net income -43.46M -38.1M -35.4M -32.51M -61.23M -4.2B -62.2M -421M -165M -2.05B -163M -160M -7.09B -26.06M -22.84M -21.22M -19.49M -36.71M -2.52B -37.29M -253M -98.78M -1.23B -97.81M -95.7M -4.25B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
22/07/26 $24.81 +1.22% 404,420
21/07/26 $24.51 +2.57% 326,248
20/07/26 $23.90 -1.10% 315,668
17/07/26 $24.16 -0.29% 242,886
16/07/26 $24.23 +0.87% 375,696
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
24.81USD
Average target price
42.78USD
Spread / Average Target
+72.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock